 Robert MacLaren
Concepts (501)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Critical Illness | 46 | 2025 | 889 | 6.500 |
Why?
| | Intensive Care Units | 41 | 2025 | 916 | 4.570 |
Why?
| | Critical Care | 27 | 2026 | 694 | 4.470 |
Why?
| | Peptic Ulcer | 9 | 2023 | 18 | 3.770 |
Why?
| | Gastrointestinal Hemorrhage | 8 | 2024 | 136 | 3.310 |
Why?
| | Hypnotics and Sedatives | 12 | 2024 | 214 | 3.120 |
Why?
| | Pharmacy Service, Hospital | 10 | 2024 | 81 | 3.020 |
Why?
| | Histamine H2 Antagonists | 9 | 2024 | 23 | 2.880 |
Why?
| | Pharmacists | 11 | 2025 | 240 | 2.780 |
Why?
| | Proton Pump Inhibitors | 9 | 2024 | 109 | 2.760 |
Why?
| | Enteral Nutrition | 13 | 2023 | 216 | 2.690 |
Why?
| | Dexmedetomidine | 9 | 2019 | 44 | 2.560 |
Why?
| | Gastric Emptying | 8 | 2017 | 36 | 1.850 |
Why?
| | Midazolam | 4 | 2024 | 72 | 1.530 |
Why?
| | Substance Withdrawal Syndrome | 5 | 2022 | 186 | 1.460 |
Why?
| | Shock, Septic | 4 | 2022 | 215 | 1.420 |
Why?
| | Epoprostenol | 2 | 2023 | 131 | 1.320 |
Why?
| | Anticoagulants | 12 | 2023 | 721 | 1.290 |
Why?
| | Heparin | 7 | 2023 | 243 | 1.280 |
Why?
| | Professional Role | 5 | 2024 | 158 | 1.170 |
Why?
| | Metoclopramide | 7 | 2010 | 19 | 1.160 |
Why?
| | Vasopressins | 4 | 2022 | 60 | 1.090 |
Why?
| | Sepsis | 7 | 2023 | 640 | 1.040 |
Why?
| | Stress, Physiological | 5 | 2021 | 453 | 1.030 |
Why?
| | Lorazepam | 4 | 2014 | 25 | 1.020 |
Why?
| | Adult | 55 | 2025 | 40262 | 0.980 |
Why?
| | Pneumonia | 5 | 2022 | 630 | 0.970 |
Why?
| | Retrospective Studies | 39 | 2024 | 17009 | 0.940 |
Why?
| | Hemorrhage | 9 | 2021 | 809 | 0.940 |
Why?
| | Humans | 119 | 2026 | 144261 | 0.920 |
Why?
| | Factor VIIa | 5 | 2016 | 43 | 0.910 |
Why?
| | Visual Acuity | 4 | 2024 | 486 | 0.890 |
Why?
| | Thromboembolism | 2 | 2020 | 125 | 0.880 |
Why?
| | Thrombelastography | 2 | 2023 | 178 | 0.880 |
Why?
| | Vasoconstrictor Agents | 5 | 2023 | 144 | 0.880 |
Why?
| | Neurosurgical Procedures | 2 | 2024 | 202 | 0.870 |
Why?
| | Gastrointestinal Agents | 5 | 2010 | 66 | 0.860 |
Why?
| | Recombinant Proteins | 13 | 2023 | 1367 | 0.860 |
Why?
| | Proton Pumps | 2 | 2014 | 8 | 0.860 |
Why?
| | Propofol | 5 | 2019 | 85 | 0.830 |
Why?
| | Ulcer | 1 | 2023 | 37 | 0.790 |
Why?
| | Retinal Degeneration | 2 | 2020 | 40 | 0.780 |
Why?
| | Alcoholism | 2 | 2022 | 808 | 0.720 |
Why?
| | Blood Coagulation Factors | 3 | 2020 | 55 | 0.710 |
Why?
| | Hypotension | 2 | 2022 | 126 | 0.690 |
Why?
| | Hypothermia, Induced | 2 | 2013 | 96 | 0.680 |
Why?
| | Oseltamivir | 1 | 2021 | 14 | 0.670 |
Why?
| | Anti-Ulcer Agents | 3 | 2017 | 12 | 0.670 |
Why?
| | Analgesia | 2 | 2018 | 105 | 0.670 |
Why?
| | Burns | 3 | 2018 | 376 | 0.660 |
Why?
| | Rhodopsin | 1 | 2020 | 11 | 0.650 |
Why?
| | Stress, Psychological | 4 | 2024 | 1147 | 0.640 |
Why?
| | Retinal Rod Photoreceptor Cells | 1 | 2020 | 17 | 0.640 |
Why?
| | Dependovirus | 1 | 2020 | 79 | 0.610 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 248 | 0.610 |
Why?
| | Vision Tests | 1 | 2019 | 22 | 0.600 |
Why?
| | Venous Thromboembolism | 2 | 2021 | 324 | 0.600 |
Why?
| | Vision, Low | 1 | 2019 | 17 | 0.600 |
Why?
| | Esomeprazole | 1 | 2018 | 7 | 0.580 |
Why?
| | Genetic Vectors | 1 | 2020 | 337 | 0.570 |
Why?
| | Fibrinolytic Agents | 3 | 2016 | 291 | 0.570 |
Why?
| | Middle Aged | 43 | 2025 | 35762 | 0.570 |
Why?
| | Pulmonary Embolism | 1 | 2021 | 243 | 0.560 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2023 | 382 | 0.560 |
Why?
| | Fluid Therapy | 3 | 2023 | 147 | 0.550 |
Why?
| | Staphylococcal Infections | 1 | 2022 | 388 | 0.550 |
Why?
| | Acute Kidney Injury | 4 | 2023 | 862 | 0.550 |
Why?
| | Genetic Therapy | 1 | 2020 | 313 | 0.540 |
Why?
| | APACHE | 3 | 2010 | 66 | 0.540 |
Why?
| | Phenytoin | 1 | 2017 | 21 | 0.540 |
Why?
| | Erythromycin | 4 | 2010 | 20 | 0.530 |
Why?
| | Albumins | 1 | 2017 | 118 | 0.510 |
Why?
| | Blood Coagulation Disorders | 2 | 2016 | 189 | 0.510 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 2 | 2015 | 25 | 0.500 |
Why?
| | Ethanol | 3 | 2022 | 625 | 0.500 |
Why?
| | Ketamine | 1 | 2018 | 132 | 0.500 |
Why?
| | Plasma | 2 | 2016 | 224 | 0.490 |
Why?
| | Male | 53 | 2025 | 72035 | 0.490 |
Why?
| | Anticonvulsants | 2 | 2017 | 234 | 0.460 |
Why?
| | Blood Coagulation | 2 | 2007 | 268 | 0.450 |
Why?
| | Glial Cell Line-Derived Neurotrophic Factor | 1 | 2015 | 17 | 0.450 |
Why?
| | Partial Thromboplastin Time | 4 | 2023 | 50 | 0.450 |
Why?
| | Hydrocortisone | 1 | 2017 | 304 | 0.440 |
Why?
| | Nitric Oxide | 1 | 2020 | 897 | 0.440 |
Why?
| | Acetaminophen | 5 | 2010 | 264 | 0.440 |
Why?
| | Nerve Growth Factor | 1 | 2015 | 34 | 0.440 |
Why?
| | Female | 50 | 2025 | 77976 | 0.440 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2014 | 28 | 0.440 |
Why?
| | Influenza, Human | 1 | 2021 | 615 | 0.430 |
Why?
| | Community-Acquired Infections | 2 | 2014 | 174 | 0.430 |
Why?
| | Aged | 28 | 2024 | 25850 | 0.430 |
Why?
| | Stomach Diseases | 2 | 2011 | 20 | 0.420 |
Why?
| | Evidence-Based Medicine | 4 | 2024 | 729 | 0.420 |
Why?
| | Epinephrine | 1 | 2015 | 155 | 0.410 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2015 | 148 | 0.410 |
Why?
| | Delphi Technique | 2 | 2026 | 329 | 0.400 |
Why?
| | Antifibrinolytic Agents | 2 | 2007 | 62 | 0.400 |
Why?
| | Erythropoietin | 2 | 2005 | 100 | 0.400 |
Why?
| | Prospective Studies | 15 | 2025 | 7970 | 0.400 |
Why?
| | Polyvinyl Chloride | 1 | 2013 | 12 | 0.400 |
Why?
| | Voriconazole | 3 | 2019 | 21 | 0.390 |
Why?
| | Hemodynamics | 2 | 2019 | 1119 | 0.380 |
Why?
| | Randomized Controlled Trials as Topic | 7 | 2023 | 1705 | 0.380 |
Why?
| | Hippocampus | 1 | 2018 | 965 | 0.380 |
Why?
| | Pain | 1 | 2018 | 777 | 0.380 |
Why?
| | Sodium Chloride | 1 | 2013 | 141 | 0.370 |
Why?
| | Drug Monitoring | 3 | 2017 | 389 | 0.360 |
Why?
| | Drug Resistance | 2 | 2011 | 153 | 0.350 |
Why?
| | Cross Infection | 4 | 2008 | 262 | 0.350 |
Why?
| | Mental Recall | 1 | 2013 | 222 | 0.350 |
Why?
| | Gastrointestinal Hormones | 1 | 2011 | 5 | 0.350 |
Why?
| | Hirudins | 4 | 2023 | 51 | 0.340 |
Why?
| | Ghrelin | 1 | 2011 | 38 | 0.340 |
Why?
| | Pseudomonas Infections | 4 | 2010 | 221 | 0.340 |
Why?
| | Double-Blind Method | 7 | 2020 | 2025 | 0.340 |
Why?
| | Heparin, Low-Molecular-Weight | 2 | 2023 | 36 | 0.340 |
Why?
| | Cisapride | 2 | 2001 | 5 | 0.340 |
Why?
| | Neuromuscular Blocking Agents | 1 | 2011 | 26 | 0.330 |
Why?
| | Cohort Studies | 8 | 2023 | 5935 | 0.330 |
Why?
| | Surveys and Questionnaires | 9 | 2026 | 6021 | 0.320 |
Why?
| | Gastrointestinal Microbiome | 1 | 2018 | 771 | 0.320 |
Why?
| | Coagulants | 2 | 2008 | 20 | 0.320 |
Why?
| | Infusions, Intravenous | 6 | 2016 | 423 | 0.320 |
Why?
| | Factor VII | 2 | 2007 | 25 | 0.320 |
Why?
| | Neuromuscular Blockade | 1 | 2011 | 51 | 0.320 |
Why?
| | Analgesics, Non-Narcotic | 2 | 2010 | 123 | 0.320 |
Why?
| | Factor Xa | 2 | 2021 | 35 | 0.310 |
Why?
| | Pharmaceutical Vehicles | 1 | 2009 | 12 | 0.310 |
Why?
| | Tachyphylaxis | 1 | 2009 | 4 | 0.310 |
Why?
| | Propylene Glycol | 1 | 2009 | 9 | 0.310 |
Why?
| | Drug Therapy, Combination | 6 | 2017 | 1044 | 0.310 |
Why?
| | Antiemetics | 3 | 2010 | 49 | 0.310 |
Why?
| | Diabetic Retinopathy | 2 | 2024 | 207 | 0.300 |
Why?
| | Protein C | 1 | 2010 | 53 | 0.300 |
Why?
| | Factor Xa Inhibitors | 2 | 2023 | 187 | 0.300 |
Why?
| | Mutation | 2 | 2020 | 4085 | 0.300 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 2 | 2023 | 19 | 0.300 |
Why?
| | Heart Arrest | 1 | 2013 | 407 | 0.300 |
Why?
| | Pseudomonas aeruginosa | 4 | 2010 | 356 | 0.290 |
Why?
| | Treatment Outcome | 14 | 2024 | 11643 | 0.290 |
Why?
| | International Normalized Ratio | 2 | 2016 | 49 | 0.290 |
Why?
| | Hemofiltration | 3 | 2017 | 24 | 0.290 |
Why?
| | Bradycardia | 3 | 2021 | 59 | 0.280 |
Why?
| | Respiration, Artificial | 6 | 2019 | 707 | 0.280 |
Why?
| | Central Serous Chorioretinopathy | 2 | 2020 | 4 | 0.280 |
Why?
| | Immune System | 1 | 2009 | 179 | 0.280 |
Why?
| | Attitude of Health Personnel | 2 | 2014 | 1182 | 0.280 |
Why?
| | Lung Diseases | 2 | 2007 | 787 | 0.270 |
Why?
| | Drug Resistance, Multiple, Bacterial | 3 | 2005 | 81 | 0.270 |
Why?
| | Antifungal Agents | 3 | 2019 | 149 | 0.270 |
Why?
| | Photochemotherapy | 2 | 2020 | 39 | 0.270 |
Why?
| | Nursing Audit | 1 | 2007 | 4 | 0.270 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2024 | 593 | 0.270 |
Why?
| | Peptide Fragments | 3 | 2023 | 698 | 0.260 |
Why?
| | Forms and Records Control | 1 | 2007 | 20 | 0.260 |
Why?
| | Hemostatics | 1 | 2007 | 61 | 0.250 |
Why?
| | Physicians | 2 | 2013 | 938 | 0.250 |
Why?
| | Triazoles | 2 | 2019 | 184 | 0.250 |
Why?
| | Risk Management | 1 | 2007 | 84 | 0.250 |
Why?
| | Tandem Mass Spectrometry | 2 | 2024 | 576 | 0.250 |
Why?
| | Bacterial Infections | 1 | 2008 | 246 | 0.250 |
Why?
| | Dopamine Antagonists | 2 | 2008 | 25 | 0.250 |
Why?
| | Hydrogen-Ion Concentration | 5 | 2014 | 561 | 0.240 |
Why?
| | Clinical Pharmacy Information Systems | 1 | 2006 | 5 | 0.240 |
Why?
| | Glutamine | 1 | 2007 | 109 | 0.240 |
Why?
| | Respiration | 1 | 2007 | 206 | 0.240 |
Why?
| | Models, Economic | 1 | 2006 | 62 | 0.240 |
Why?
| | Anti-Bacterial Agents | 5 | 2022 | 1906 | 0.230 |
Why?
| | Factor VII Deficiency | 1 | 2005 | 5 | 0.230 |
Why?
| | Anesthesia | 1 | 2009 | 257 | 0.230 |
Why?
| | Anesthetics | 1 | 2007 | 99 | 0.230 |
Why?
| | Practice Patterns, Physicians' | 1 | 2014 | 1347 | 0.220 |
Why?
| | Fentanyl | 3 | 2018 | 126 | 0.220 |
Why?
| | Common Data Elements | 1 | 2025 | 15 | 0.220 |
Why?
| | Intubation, Gastrointestinal | 2 | 2008 | 82 | 0.220 |
Why?
| | Risk Factors | 9 | 2023 | 10699 | 0.210 |
Why?
| | Analgesics, Opioid | 3 | 2018 | 1131 | 0.210 |
Why?
| | Intravitreal Injections | 1 | 2024 | 71 | 0.210 |
Why?
| | Aged, 80 and over | 9 | 2024 | 8243 | 0.210 |
Why?
| | Macular Edema | 1 | 2024 | 48 | 0.210 |
Why?
| | Clinical Trials as Topic | 4 | 2017 | 1050 | 0.210 |
Why?
| | Drug Interactions | 2 | 2023 | 397 | 0.200 |
Why?
| | Antidotes | 2 | 2016 | 145 | 0.200 |
Why?
| | Regression Analysis | 3 | 2017 | 998 | 0.200 |
Why?
| | Anemia | 1 | 2005 | 187 | 0.200 |
Why?
| | Time Factors | 10 | 2018 | 7155 | 0.200 |
Why?
| | Patients' Rooms | 1 | 2022 | 13 | 0.190 |
Why?
| | Clostridium Infections | 2 | 2014 | 74 | 0.190 |
Why?
| | Saline Solution, Hypertonic | 1 | 2023 | 42 | 0.190 |
Why?
| | Cross-Over Studies | 3 | 2020 | 600 | 0.190 |
Why?
| | Angiogenesis Inhibitors | 1 | 2024 | 236 | 0.190 |
Why?
| | Biological Availability | 1 | 2023 | 142 | 0.190 |
Why?
| | Erythrocyte Transfusion | 1 | 2005 | 230 | 0.190 |
Why?
| | Microbial Sensitivity Tests | 3 | 2018 | 370 | 0.180 |
Why?
| | United States | 9 | 2024 | 15876 | 0.180 |
Why?
| | Warfarin | 2 | 2007 | 170 | 0.180 |
Why?
| | Predictive Value of Tests | 3 | 2017 | 2111 | 0.180 |
Why?
| | Antacids | 1 | 2001 | 16 | 0.180 |
Why?
| | Minnesota | 1 | 2022 | 169 | 0.180 |
Why?
| | Renal Replacement Therapy | 2 | 2015 | 99 | 0.180 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2024 | 557 | 0.180 |
Why?
| | Colorado | 7 | 2017 | 4562 | 0.180 |
Why?
| | Research Design | 2 | 2026 | 1129 | 0.170 |
Why?
| | Myocardial Infarction | 1 | 2009 | 1208 | 0.170 |
Why?
| | Anti-Infective Agents | 1 | 2004 | 242 | 0.170 |
Why?
| | Health Care Costs | 1 | 2005 | 421 | 0.170 |
Why?
| | Vitamin K 1 | 1 | 2001 | 1 | 0.170 |
Why?
| | Norepinephrine | 1 | 2022 | 196 | 0.170 |
Why?
| | Prothrombin | 1 | 2021 | 25 | 0.170 |
Why?
| | Stomach Ulcer | 2 | 2019 | 12 | 0.170 |
Why?
| | Pharmaceutical Preparations | 1 | 2023 | 169 | 0.170 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2001 | 32 | 0.170 |
Why?
| | United Kingdom | 2 | 2019 | 336 | 0.170 |
Why?
| | Incidence | 3 | 2022 | 2870 | 0.160 |
Why?
| | Statistics, Nonparametric | 3 | 2016 | 427 | 0.160 |
Why?
| | Catheters | 1 | 2021 | 75 | 0.160 |
Why?
| | Light Coagulation | 1 | 2020 | 10 | 0.160 |
Why?
| | Gene Knock-In Techniques | 1 | 2020 | 61 | 0.160 |
Why?
| | Decision Support Techniques | 3 | 2014 | 454 | 0.160 |
Why?
| | Resuscitation | 1 | 2023 | 302 | 0.160 |
Why?
| | Retinitis Pigmentosa | 1 | 2019 | 20 | 0.150 |
Why?
| | Area Under Curve | 3 | 2014 | 329 | 0.150 |
Why?
| | Length of Stay | 4 | 2014 | 1335 | 0.150 |
Why?
| | Thrombolytic Therapy | 1 | 2021 | 162 | 0.150 |
Why?
| | Inflammation | 1 | 2011 | 2877 | 0.150 |
Why?
| | Ischemia | 1 | 2023 | 421 | 0.150 |
Why?
| | Photosensitizing Agents | 2 | 2020 | 42 | 0.150 |
Why?
| | Adrenal Cortex Hormones | 1 | 2002 | 478 | 0.150 |
Why?
| | Invasive Fungal Infections | 1 | 2019 | 11 | 0.150 |
Why?
| | Electric Stimulation Therapy | 1 | 2019 | 62 | 0.150 |
Why?
| | Enzyme Inhibitors | 1 | 2002 | 824 | 0.150 |
Why?
| | Refraction, Ocular | 1 | 2019 | 47 | 0.150 |
Why?
| | Retinal Pigment Epithelium | 1 | 2019 | 80 | 0.150 |
Why?
| | Biometry | 1 | 2019 | 68 | 0.150 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2014 | 2026 | 0.150 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2019 | 80 | 0.140 |
Why?
| | Restraint, Physical | 1 | 2018 | 75 | 0.140 |
Why?
| | Disease Models, Animal | 2 | 2020 | 4556 | 0.140 |
Why?
| | Administration, Inhalation | 1 | 2020 | 574 | 0.140 |
Why?
| | Patient Care | 1 | 2019 | 118 | 0.140 |
Why?
| | Stem Cell Transplantation | 1 | 2019 | 191 | 0.140 |
Why?
| | Hospital Costs | 2 | 2009 | 124 | 0.140 |
Why?
| | Vasoconstriction | 2 | 2023 | 217 | 0.140 |
Why?
| | Burnout, Professional | 1 | 2025 | 484 | 0.140 |
Why?
| | Random Allocation | 1 | 2018 | 363 | 0.130 |
Why?
| | Nitriles | 1 | 2019 | 205 | 0.130 |
Why?
| | Patient Satisfaction | 1 | 2022 | 704 | 0.130 |
Why?
| | RNA, Bacterial | 1 | 2018 | 189 | 0.130 |
Why?
| | Fat Emulsions, Intravenous | 1 | 1997 | 29 | 0.130 |
Why?
| | Vancomycin | 1 | 2018 | 93 | 0.130 |
Why?
| | Hepatorenal Syndrome | 2 | 2009 | 15 | 0.130 |
Why?
| | Pharmacoepidemiology | 2 | 2014 | 22 | 0.130 |
Why?
| | Cross-Sectional Studies | 3 | 2020 | 5813 | 0.130 |
Why?
| | Oxygen | 1 | 2023 | 995 | 0.130 |
Why?
| | Critical Care Nursing | 1 | 2018 | 51 | 0.130 |
Why?
| | Antibodies, Bacterial | 1 | 2018 | 148 | 0.130 |
Why?
| | Anesthetics, Intravenous | 1 | 1997 | 69 | 0.130 |
Why?
| | Sucralfate | 1 | 2017 | 5 | 0.130 |
Why?
| | Piracetam | 1 | 2017 | 14 | 0.130 |
Why?
| | Immunity, Humoral | 1 | 2018 | 120 | 0.130 |
Why?
| | Cost-Benefit Analysis | 2 | 2014 | 623 | 0.130 |
Why?
| | Pneumococcal Vaccines | 1 | 2018 | 130 | 0.130 |
Why?
| | Drug Compounding | 2 | 2017 | 107 | 0.130 |
Why?
| | Retina | 1 | 2019 | 323 | 0.120 |
Why?
| | Drug Therapy | 1 | 2017 | 80 | 0.120 |
Why?
| | Administration, Oral | 5 | 2017 | 847 | 0.120 |
Why?
| | Nitroprusside | 1 | 2016 | 72 | 0.120 |
Why?
| | Thiocyanates | 1 | 2016 | 28 | 0.120 |
Why?
| | Thiosulfates | 1 | 2016 | 19 | 0.120 |
Why?
| | Intracranial Hemorrhages | 1 | 2017 | 100 | 0.120 |
Why?
| | Wounds and Injuries | 1 | 2025 | 952 | 0.120 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2019 | 276 | 0.120 |
Why?
| | Analgesics | 1 | 2018 | 228 | 0.120 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2018 | 558 | 0.120 |
Why?
| | Therapeutics | 1 | 2015 | 13 | 0.110 |
Why?
| | Peptic Ulcer Hemorrhage | 1 | 2014 | 5 | 0.110 |
Why?
| | Placebo Effect | 1 | 2015 | 25 | 0.110 |
Why?
| | Academic Medical Centers | 3 | 2019 | 545 | 0.110 |
Why?
| | Mice, Transgenic | 1 | 2020 | 2182 | 0.110 |
Why?
| | beta-Cyclodextrins | 1 | 2015 | 32 | 0.110 |
Why?
| | Antiviral Agents | 1 | 2021 | 767 | 0.110 |
Why?
| | Methanol | 1 | 2015 | 46 | 0.110 |
Why?
| | Respiratory Insufficiency | 1 | 1998 | 326 | 0.110 |
Why?
| | Thrombosis | 1 | 2019 | 393 | 0.110 |
Why?
| | Program Development | 1 | 2017 | 369 | 0.110 |
Why?
| | Multivariate Analysis | 3 | 2017 | 1533 | 0.110 |
Why?
| | Pyridines | 1 | 2019 | 605 | 0.110 |
Why?
| | Treatment Failure | 2 | 2020 | 363 | 0.110 |
Why?
| | Vitreoretinopathy, Proliferative | 1 | 2014 | 14 | 0.110 |
Why?
| | Vasodilator Agents | 1 | 2016 | 331 | 0.110 |
Why?
| | Pain Management | 1 | 2018 | 405 | 0.110 |
Why?
| | Cardiopulmonary Bypass | 1 | 2016 | 221 | 0.100 |
Why?
| | Practice Guidelines as Topic | 4 | 2015 | 1559 | 0.100 |
Why?
| | Acute Disease | 3 | 2008 | 1028 | 0.100 |
Why?
| | Shivering | 1 | 2013 | 5 | 0.100 |
Why?
| | Stress Disorders, Traumatic, Acute | 1 | 2013 | 7 | 0.100 |
Why?
| | Osmotic Pressure | 1 | 2014 | 39 | 0.100 |
Why?
| | Immunoglobulin G | 1 | 2018 | 893 | 0.100 |
Why?
| | Gene Expression | 1 | 2018 | 1487 | 0.100 |
Why?
| | Laser Therapy | 1 | 2015 | 135 | 0.100 |
Why?
| | Tomography, Optical Coherence | 3 | 2024 | 264 | 0.100 |
Why?
| | Pneumonia, Ventilator-Associated | 1 | 2014 | 57 | 0.100 |
Why?
| | Genetic Markers | 1 | 2014 | 331 | 0.100 |
Why?
| | Consensus | 2 | 2026 | 488 | 0.100 |
Why?
| | Neurologic Examination | 1 | 2013 | 130 | 0.100 |
Why?
| | Thrombocytopenia | 3 | 2018 | 205 | 0.100 |
Why?
| | Benzodiazepines | 1 | 2014 | 165 | 0.100 |
Why?
| | Drug Storage | 1 | 2013 | 53 | 0.100 |
Why?
| | Liver Diseases | 1 | 2016 | 304 | 0.100 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2013 | 131 | 0.100 |
Why?
| | Microphthalmos | 1 | 2013 | 2 | 0.100 |
Why?
| | Drug Packaging | 1 | 2013 | 41 | 0.100 |
Why?
| | Medicare | 2 | 2009 | 881 | 0.100 |
Why?
| | Hemostasis | 2 | 2019 | 102 | 0.100 |
Why?
| | Drug Stability | 1 | 2013 | 164 | 0.100 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2013 | 178 | 0.090 |
Why?
| | Injections | 1 | 2013 | 196 | 0.090 |
Why?
| | Health Care Surveys | 1 | 2014 | 538 | 0.090 |
Why?
| | Lens Implantation, Intraocular | 1 | 2013 | 80 | 0.090 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2023 | 257 | 0.090 |
Why?
| | Canada | 3 | 2017 | 428 | 0.090 |
Why?
| | Propensity Score | 1 | 2014 | 367 | 0.090 |
Why?
| | Motilin | 1 | 2011 | 1 | 0.090 |
Why?
| | Cholecystokinin | 1 | 2011 | 15 | 0.090 |
Why?
| | Models, Genetic | 1 | 2014 | 535 | 0.090 |
Why?
| | Respiratory Aspiration | 1 | 2011 | 32 | 0.090 |
Why?
| | Phacoemulsification | 1 | 2013 | 122 | 0.080 |
Why?
| | Societies, Pharmaceutical | 2 | 2020 | 14 | 0.080 |
Why?
| | Renal Dialysis | 1 | 2015 | 462 | 0.080 |
Why?
| | Animals | 5 | 2020 | 38030 | 0.080 |
Why?
| | Drug Administration Schedule | 4 | 2018 | 778 | 0.080 |
Why?
| | Drug Resistance, Multiple | 1 | 2010 | 25 | 0.080 |
Why?
| | Intraoperative Complications | 2 | 2013 | 155 | 0.080 |
Why?
| | RNA, Messenger | 1 | 2018 | 2829 | 0.080 |
Why?
| | Adolescent | 8 | 2019 | 22281 | 0.080 |
Why?
| | Biomedical Research | 1 | 2017 | 709 | 0.080 |
Why?
| | Lactoferrin | 1 | 2010 | 36 | 0.080 |
Why?
| | Contraindications | 1 | 2010 | 91 | 0.080 |
Why?
| | Hospitals, University | 2 | 2008 | 176 | 0.080 |
Why?
| | Severity of Illness Index | 2 | 2015 | 2917 | 0.080 |
Why?
| | Mice, Inbred C57BL | 2 | 2018 | 5988 | 0.070 |
Why?
| | Multiple Organ Failure | 1 | 2010 | 124 | 0.070 |
Why?
| | Imipenem | 2 | 2010 | 16 | 0.070 |
Why?
| | Databases, Factual | 2 | 2018 | 1484 | 0.070 |
Why?
| | Observer Variation | 1 | 2010 | 354 | 0.070 |
Why?
| | Kidney Failure, Chronic | 1 | 2015 | 597 | 0.070 |
Why?
| | Hypoglycemia | 1 | 2013 | 477 | 0.070 |
Why?
| | Diagnostic Errors | 1 | 2010 | 175 | 0.070 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2010 | 139 | 0.070 |
Why?
| | Follow-Up Studies | 4 | 2024 | 5389 | 0.070 |
Why?
| | Risk Assessment | 2 | 2014 | 3637 | 0.070 |
Why?
| | Data Interpretation, Statistical | 1 | 2010 | 371 | 0.070 |
Why?
| | Pilot Projects | 1 | 2013 | 1867 | 0.070 |
Why?
| | Patient Care Team | 1 | 2013 | 686 | 0.070 |
Why?
| | Vitamin K | 1 | 2007 | 45 | 0.070 |
Why?
| | Blood Pressure | 2 | 2004 | 1759 | 0.070 |
Why?
| | Quality Improvement | 3 | 2020 | 1285 | 0.060 |
Why?
| | Gene Expression Profiling | 1 | 2014 | 1782 | 0.060 |
Why?
| | Databases as Topic | 1 | 2007 | 71 | 0.060 |
Why?
| | Magnesium | 1 | 2007 | 155 | 0.060 |
Why?
| | Phosphorus | 1 | 2007 | 99 | 0.060 |
Why?
| | Potassium | 1 | 2007 | 152 | 0.060 |
Why?
| | Cost Control | 1 | 2006 | 37 | 0.060 |
Why?
| | Cellulitis | 1 | 2007 | 53 | 0.060 |
Why?
| | Burn Units | 1 | 2007 | 48 | 0.060 |
Why?
| | Cerebral Hemorrhage | 1 | 2007 | 120 | 0.060 |
Why?
| | Biomarkers | 2 | 2015 | 4254 | 0.060 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2011 | 1217 | 0.060 |
Why?
| | Antihypertensive Agents | 1 | 2010 | 509 | 0.060 |
Why?
| | Anxiety | 1 | 2013 | 1104 | 0.060 |
Why?
| | Societies, Medical | 2 | 2020 | 886 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2014 | 3403 | 0.060 |
Why?
| | Economics, Pharmaceutical | 1 | 2005 | 10 | 0.060 |
Why?
| | Pipecolic Acids | 1 | 2005 | 24 | 0.060 |
Why?
| | Fibrinolysis | 1 | 2007 | 162 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 1 | 2014 | 2359 | 0.060 |
Why?
| | Kidney Diseases | 1 | 2009 | 425 | 0.060 |
Why?
| | Arginine Vasopressin | 1 | 2005 | 44 | 0.060 |
Why?
| | Octreotide | 1 | 2005 | 23 | 0.060 |
Why?
| | Time and Motion Studies | 1 | 2025 | 28 | 0.060 |
Why?
| | Ranibizumab | 1 | 2024 | 21 | 0.050 |
Why?
| | Costs and Cost Analysis | 1 | 2005 | 218 | 0.050 |
Why?
| | Quality-Adjusted Life Years | 1 | 2005 | 117 | 0.050 |
Why?
| | Blood Component Transfusion | 1 | 2005 | 103 | 0.050 |
Why?
| | Ceftazidime | 1 | 2004 | 7 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2014 | 3592 | 0.050 |
Why?
| | beta-Lactam Resistance | 1 | 2004 | 9 | 0.050 |
Why?
| | Mice | 2 | 2020 | 18329 | 0.050 |
Why?
| | Intraocular Pressure | 2 | 2019 | 327 | 0.050 |
Why?
| | Ciprofloxacin | 1 | 2004 | 26 | 0.050 |
Why?
| | Drug Substitution | 1 | 2024 | 63 | 0.050 |
Why?
| | Sentinel Surveillance | 1 | 2004 | 46 | 0.050 |
Why?
| | Tobramycin | 1 | 2004 | 54 | 0.050 |
Why?
| | Urine | 1 | 2004 | 62 | 0.050 |
Why?
| | Wet Macular Degeneration | 1 | 2024 | 57 | 0.050 |
Why?
| | Bevacizumab | 1 | 2024 | 167 | 0.050 |
Why?
| | Hospitals, Teaching | 1 | 2004 | 119 | 0.050 |
Why?
| | Depression | 1 | 2013 | 1533 | 0.050 |
Why?
| | Hospitals, Urban | 1 | 2004 | 144 | 0.050 |
Why?
| | Sex Factors | 1 | 2009 | 2096 | 0.050 |
Why?
| | Neoplasms | 1 | 2018 | 2870 | 0.050 |
Why?
| | Models, Biological | 1 | 2010 | 1820 | 0.050 |
Why?
| | Skin Diseases | 1 | 2004 | 149 | 0.050 |
Why?
| | Adrenal Cortex | 1 | 2002 | 33 | 0.050 |
Why?
| | Liver Transplantation | 1 | 2009 | 822 | 0.050 |
Why?
| | Age Factors | 1 | 2009 | 3313 | 0.040 |
Why?
| | Pneumonia, Bacterial | 1 | 2003 | 113 | 0.040 |
Why?
| | Hospital Mortality | 1 | 2007 | 1027 | 0.040 |
Why?
| | Chronic Disease | 2 | 2020 | 1812 | 0.040 |
Why?
| | Hypertension | 1 | 2010 | 1254 | 0.040 |
Why?
| | Hospitals | 1 | 2006 | 727 | 0.040 |
Why?
| | Gastrointestinal Motility | 1 | 2000 | 29 | 0.040 |
Why?
| | Young Adult | 4 | 2019 | 13990 | 0.040 |
Why?
| | Gastric Mucosa | 1 | 2000 | 52 | 0.040 |
Why?
| | Subretinal Fluid | 1 | 2020 | 1 | 0.040 |
Why?
| | Stomach | 1 | 2000 | 109 | 0.040 |
Why?
| | Lasers, Semiconductor | 1 | 2020 | 11 | 0.040 |
Why?
| | Therapeutic Index | 1 | 2020 | 3 | 0.040 |
Why?
| | Methadone | 1 | 2001 | 110 | 0.040 |
Why?
| | Indocyanine Green | 1 | 2020 | 42 | 0.040 |
Why?
| | Heart Rate | 1 | 2004 | 849 | 0.040 |
Why?
| | Sickness Impact Profile | 1 | 2020 | 62 | 0.040 |
Why?
| | Coloring Agents | 1 | 2020 | 93 | 0.040 |
Why?
| | Cost Savings | 1 | 2000 | 86 | 0.040 |
Why?
| | Quality of Health Care | 1 | 2025 | 688 | 0.040 |
Why?
| | Electroretinography | 1 | 2019 | 50 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 2001 | 527 | 0.040 |
Why?
| | Placebos | 1 | 2000 | 192 | 0.040 |
Why?
| | Intestinal Absorption | 1 | 2000 | 103 | 0.040 |
Why?
| | Causality | 1 | 2019 | 126 | 0.040 |
Why?
| | Fluorescein Angiography | 1 | 2020 | 184 | 0.040 |
Why?
| | Linear Models | 1 | 2001 | 850 | 0.030 |
Why?
| | Nausea | 1 | 1998 | 111 | 0.030 |
Why?
| | Data Collection | 1 | 2001 | 633 | 0.030 |
Why?
| | Equipment Design | 1 | 2019 | 530 | 0.030 |
Why?
| | Child | 2 | 2017 | 22537 | 0.030 |
Why?
| | Vomiting | 1 | 1998 | 130 | 0.030 |
Why?
| | Parenteral Nutrition, Total | 1 | 1997 | 30 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2018 | 169 | 0.030 |
Why?
| | New Zealand | 1 | 2017 | 54 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2017 | 170 | 0.030 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2019 | 244 | 0.030 |
Why?
| | Australia | 1 | 2017 | 286 | 0.030 |
Why?
| | Netherlands | 1 | 2015 | 82 | 0.030 |
Why?
| | Quality of Life | 2 | 2020 | 3166 | 0.030 |
Why?
| | Vision, Ocular | 1 | 2015 | 46 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2017 | 221 | 0.030 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2015 | 53 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2017 | 402 | 0.030 |
Why?
| | Emergency Service, Hospital | 1 | 2007 | 2301 | 0.030 |
Why?
| | Standard of Care | 1 | 2014 | 80 | 0.030 |
Why?
| | Eye Proteins | 1 | 2014 | 90 | 0.030 |
Why?
| | Clinical Protocols | 1 | 2015 | 282 | 0.030 |
Why?
| | Crohn Disease | 1 | 1997 | 260 | 0.030 |
Why?
| | Acidosis | 1 | 2015 | 105 | 0.030 |
Why?
| | Retinal Detachment | 1 | 2014 | 71 | 0.020 |
Why?
| | Seizures | 1 | 2017 | 460 | 0.020 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2014 | 419 | 0.020 |
Why?
| | Axial Length, Eye | 1 | 2013 | 16 | 0.020 |
Why?
| | Rats | 1 | 2001 | 5592 | 0.020 |
Why?
| | Tonometry, Ocular | 1 | 2013 | 103 | 0.020 |
Why?
| | ROC Curve | 1 | 2014 | 612 | 0.020 |
Why?
| | Logistic Models | 1 | 2017 | 2104 | 0.020 |
Why?
| | Risk | 1 | 2014 | 909 | 0.020 |
Why?
| | Recovery of Function | 1 | 2015 | 706 | 0.020 |
Why?
| | Genes, Regulator | 1 | 2010 | 35 | 0.020 |
Why?
| | Antithrombins | 1 | 2010 | 70 | 0.020 |
Why?
| | Odds Ratio | 1 | 2013 | 1072 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 330 | 0.020 |
Why?
| | Microcirculation | 1 | 2010 | 138 | 0.020 |
Why?
| | Genotype | 1 | 2014 | 1833 | 0.020 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2009 | 38 | 0.020 |
Why?
| | Drug Utilization | 1 | 2008 | 166 | 0.020 |
Why?
| | Liver Cirrhosis | 1 | 2009 | 288 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2010 | 1253 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 1997 | 2730 | 0.020 |
Why?
| | Drug Costs | 1 | 2008 | 115 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2014 | 2143 | 0.020 |
Why?
| | Thienamycins | 1 | 2005 | 3 | 0.010 |
Why?
| | Polymyxin B | 1 | 2005 | 20 | 0.010 |
Why?
| | Inpatients | 1 | 2010 | 542 | 0.010 |
Why?
| | Colistin | 1 | 2005 | 10 | 0.010 |
Why?
| | Antidiuretic Agents | 1 | 2005 | 5 | 0.010 |
Why?
| | Platelet Aggregation | 1 | 2005 | 103 | 0.010 |
Why?
| | Platelet Activation | 1 | 2005 | 103 | 0.010 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2004 | 72 | 0.010 |
Why?
| | Arginine | 1 | 2005 | 262 | 0.010 |
Why?
| | Hospitalization | 1 | 2014 | 2424 | 0.010 |
Why?
| | Endothelial Cells | 1 | 2010 | 869 | 0.010 |
Why?
| | Guideline Adherence | 1 | 2008 | 586 | 0.010 |
Why?
| | DNA | 1 | 2010 | 1460 | 0.010 |
Why?
| | Drug Resistance, Microbial | 1 | 2003 | 69 | 0.010 |
Why?
| | Kidney Transplantation | 1 | 2009 | 704 | 0.010 |
Why?
| | Algorithms | 1 | 2010 | 1834 | 0.010 |
Why?
| | Transcription Factors | 1 | 2010 | 1739 | 0.010 |
Why?
| | Cardiac Surgical Procedures | 1 | 2008 | 609 | 0.010 |
Why?
| | Sulfonamides | 1 | 2005 | 580 | 0.010 |
Why?
| | Population Surveillance | 1 | 2004 | 483 | 0.010 |
Why?
| | Liver | 1 | 2010 | 1884 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2013 | 2916 | 0.010 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2001 | 284 | 0.010 |
Why?
|
|
MacLaren's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|